Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 RET/PTC activation in human thyroid carcinomas.

Literature DB >> 7629379

RET/PTC activation in human thyroid carcinomas.

A Fusco¹, M Santoro, M Grieco, F Carlomagno, N Dathan, N Fabien, M T Berlingieri, Z Li, V De Franciscis, D Salvatore.

Abstract

Entities: Disease Gene Species

Mesh：

Year: 1995 PMID： 7629379 DOI： 10.1007/BF03349720

Source DB: PubMed Journal: J Endocrinol Invest ISSN： 0391-4097 Impact factor: 4.256

× No keyword cloud information.

9 in total

1. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A.

Authors: I Bongarzone; N Monzini; M G Borrello; C Carcano; G Ferraresi; E Arighi; P Mondellini; G Della Porta; M A Pierotti
Journal: Mol Cell Biol Date: 1993-01 Impact factor: 4.272

2. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.

Authors: M Grieco; M Santoro; M T Berlingieri; R M Melillo; R Donghi; I Bongarzone; M A Pierotti; G Della Porta; A Fusco; G Vecchio
Journal: Cell Date: 1990-02-23 Impact factor: 41.582

3. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Authors: M Santoro; F Carlomagno; I D Hay; M A Herrmann; M Grieco; R Melillo; M A Pierotti; I Bongarzone; G Della Porta; N Berger
Journal: J Clin Invest Date: 1992-05 Impact factor: 14.808

4. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas.

Authors: M Santoro; R Rosati; M Grieco; M T Berlingieri; G L D'Amato; V de Franciscis; A Fusco
Journal: Oncogene Date: 1990-10 Impact factor: 9.867

5. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.

Authors: M Santoro; N A Dathan; M T Berlingieri; I Bongarzone; C Paulin; M Grieco; M A Pierotti; G Vecchio; A Fusco
Journal: Oncogene Date: 1994-02 Impact factor: 9.867

6. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC.

Authors: M A Pierotti; M Santoro; R B Jenkins; G Sozzi; I Bongarzone; M Grieco; N Monzini; M Miozzo; M A Herrmann; A Fusco
Journal: Proc Natl Acad Sci U S A Date: 1992-03-01 Impact factor: 11.205

3 in total

RET/PTC activation in human thyroid carcinomas.

1. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A.

2. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.

3. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

4. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas.

5. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.

6. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC.

7. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

8. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

9. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases.

Review 1. Etiology and significance of the optically clear nucleus.

2. Inhibition of oncogene-induced inflammatory chemokines using a farnesyltransferase inhibitor.

Review 3. Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma.